英文药名：SYNVISC（Sodium Hyaluronate Crosslinked Polymer/with vinylsulfone）

中文药名：透明质酸钠注射器

适合病症：骨关节炎的疼痛缓解

生产厂家：赛诺菲/帝人制药

サイビスクディスポ関節注２mL

治疗类别名称
钠的透明质酸的交联制剂
商標名
SYNVISC ２mL
一般名
ヒアルロン酸ナトリウム架橋処理ポリマー（Sodium Hyaluronate Crosslinked Polymer）
本　質
该产品，透明质酸衍生物（分子量：约600万）由甲醛处理从梳子健康鸡，透明质酸和蛋白质是交联的。
一般名
ヒアルロン酸ナトリウム架橋処理ポリマービニルスルホン架橋体（Sodium Hyaluronate Crosslinked Polymer Crosslinked with vinylsulfone）
本　質
该产品是一种透明质酸衍生物：在（分子量6,000,000以上），钠交联处理的聚合物的透明质酸是交联的由二乙烯基砜的处理。
适合病症：
在患者膝关节保守非药物治疗和口服药物的骨关节炎的疼痛缓解具有足够的反应，而不是痛苦。
用法用量
通常，一个成年人一次2mL的3个连续的每周（14.4mg和1.6mg透明质酸钠交联处理的聚合物的乙烯基砜交联透明质酸钠的交联聚合物加工），给药至膝关节腔内。
包装规格
一次性联合注2毫升：1注射器

制造和销售
赛诺菲公司[联盟]帝人制药
完整处方资料附件：http://www.info.pmda.go.jp/go/pack/3999428G1023_2_02/
Therapeutic category name
Sodium hyaluronic acid cross-linked formulation
Brand Name
Sai bisque disposable joint Note 2mL
composition
Active ingredient
Containing sodium hyaluronate crosslinking treatment polymer 14.4mg and sodium crosslinking treatment polymer vinyl sulfone cross-linked hyaluronic acid 1.6mg in one syringe (2mL).
Additive
Sodium chloride
Sodium dihydrogen phosphate
Disodium hydrogen phosphate
Contraindication
Patient component or sodium hyaluronate of this drug, birds of proteins, feathers, for the eggs with a history of hypersensitivity
Efficacy or effect
Pain relief in patients with osteoarthritis of the knee to conservative non-drug therapy and oral medication has a sufficient response and not pain
Usually, an adult once 2mL 3 consecutive per week (14.4mg and 1.6mg as hyaluronic acid sodium cross-linking treatment polymer vinyl sulfone cross-linked as sodium hyaluronate crosslinked polymer processing), administered to the knee joint cavity.
The use of this drug, a continuous three doses per week and 1 cool, and Principle 1 cool.
The efficacy and safety of multiple times cool not been established. [The drug is compared to the first cool, in the second course after it has been reported that adverse events will increase. ]
Since this drug is administered within the joint, it is carried out under strict aseptic operation.
Careful administration
There is a risk of complications due to infection of the decrease in the injection site of the stasis patient is observed [blood circulation of venous blood or lymph to the joint side of the lower limb to be treated. ]
A liver disorder or history that there is a fear that worsen the patient [liver failure. ]
For patients [this drug there is a skin disease or infection in administration joint is to be administered within the joint. ]
Clinically significant adverse reactions
Shock, anaphylactic-like symptoms (both frequency unknown Note 1)):
Shock, anaphylactoid symptoms may occur. Patients should be carefully monitored, and if any abnormalities are observed, administration should be discontinued and appropriate treatment.
※ arthritis (frequency unknown Note 1)):
Fever, pain, because it may arthritis with edema appears, the patient was fully explained, if such symptoms appear, to take such appropriate corresponding instructed to contact their physician.
Pharmacology
Pain-relieving action
In the normal knee joints and inflammation of the knee joint cat, it reduces the nerve response from the pain receptors afferent nerve fibers, pain-relieving effect was observed 5).
In the normal knee joint and knee joint inflammation in rats, 6 pain relief effect was observed to reduce the pain induced neuronal activity).
Physicochemical knowledge of active ingredient
Generic name
Sodium cross-linking treatment polymer hyaluronic acid (Sodium Hyaluronate Crosslinked Polymer)
This quality
The product, a hyaluronic acid derivative (molecular weight: about 6,000,000) from combs healthy chickens, hyaluronic acid and the proteins are cross-linked by formaldehyde treatment.
Generic name
Sodium hyaluronate crosslinking treatment polymer vinyl sulfone cross-linked product (Sodium Hyaluronate Crosslinked Polymer Crosslinked with vinylsulfone)
This quality
The product is a hyaluronic acid derivative: in (molecular weight of 6,000,000 or more), sodium cross-linking treatment polymer hyaluronic acid are cross-linked by divinyl sulfone processing.